This is consistent with a previous study, in pancreatic cancer, where Sesn2 can increase glycolysis and promote the proliferation of pancreatic cancer cells, and both of these pro-tumorigenic effects were reversed by mTOR inhibitors [33]. This evidence concerns the gene SESN2 and familial pancreatic carcinoma.